Vascular endothelial growth factor gene transfer for diabetic polyneuropathy: A randomized, double‐blinded trial

Abstract

Intramuscular plasmid VEGF gene transfer improved diabetic neuropathic symptoms, meeting primary end-point criteria for efficacy but not affecting most secondary measures. Treatment was associated with more serious adverse events that did not reach statistical significance. These results are not conclusive but may justify further clinical study.